Viking Enters Weight-Loss Arena with Promising Phase I Data
Tuesday, Viking Therapeutics released Phase I results for its weight-loss candidate VK2735, which demonstrated a good safety and tolerability profile and resulted in significant weight reductions.
Viking Enters Weight-Loss Arena with Promising Phase I Data Read More »
